Alzheon Pharmaceutical vector logo
Alzheon is also developing a pipeline of additional novel AD therapeutics, including ALZ-101, a tau aggregation inhibitor, and ALZ-201, an alpha-synuclein aggregation inhibitor. These programs are based on Alzheon's proprietary technology platform, which identifies and targets key pathological processes in AD.
